Overcoming Treatment Challenges in the Treatment-Experienced Patient With HIV
This CME activity is provided by OA Education.
This program is sponsored by Medical Education Resources, Inc., a nonprofit medical education organization, and supported through an educational grant from Ortho Biotech and Tibotec Therapeutics.
Medical Education Resources is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
Medical Education Resources designates this educational activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This CME activity was planned and produced in accordance with the ACCME Essentials.
Medical Education Resources is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
This CE activity provides 1.8 contact hours (2006) and 1.5 contact hours (2007). Provider approval expires July 31, 2007.
Provider approved by the California Board of Registered Nursing, Provider #CEP 12299, for 1.8 contact hours (2006) and 1.5 contact hours (2007).
Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Statements of credit will be mailed within six to eight weeks of receipt of appropriate documentation.
Universal Program Number: 816-000-06-059-H02
The continued development of new antiretroviral agents has led to significant improvements in how HIV is managed by healthcare providers. Currently, there are more than 25 agents approved for the treatment of HIV infection; however, despite a significant decrease in HIV-related morbidity and mortality, current regimens face increasing problems with drug resistance, cross-resistance between different classes of antiretrovirals, and long-term toxicity. Therefore, in addition to further improving currently available antiretroviral drugs, there is a clear and increasingly urgent need for the development of new drugs that target different aspects of the HIV life cycle to overcome these therapeutic challenges in the treatment-experienced patient with HIV. New therapies, such as non-peptidic protease inhibitors (PIs), new-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), entry inhibitors, integrase inhibitors, and maturation inhibitors, have the potential to offer significant benefits and overcome the challenges of treating patients with extensive treatment histories or with highly drug-resistant HIV. Of these therapies, the PIs and NNRTIs have realized the most significant development to date. However, treatment-related toxicities continue to represent additional challenges that can significantly affect the patients' overall well-being and possibly interfere with treatment adherence.
This activity will review novel antiretroviral agents and discuss treatment-related issues in the management of treatment-experienced patient with HIV.
This activity is designed for physicians, nurses, and pharmacists involved in the clinical care and treatment of patients with HIV.
After participating in this activity, participants should be able to:
Completion of this continuing-education activity should take approximately 1.5 hours. Please follow the steps below to ensure your successful completion of this activity and receipt of credit:
A standard Web browser, such as Internet Explorer or Firefox, an Internet connection, and Flash 6 player or later are necessary for participation in this activity.
This article was provided by TheBodyPRO.